PD Prescription Guide: Assumptions on which Modeling is Based

Assumptions on which Modeling is Based

Data from 1,006 randomly selected adult PD patients from 39 U.S. centers were analyzed and used to group patients according to their peritoneal membrane transport characteristics and Vurea. Based on four PET classifications and three Vurea categories, modeling was performed on PD Adequest to obtain prescriptions that would meet or exceed minimum adequacy and UF goals.11

Clearance goals have been subject to multiple revisions. The sample prescriptions provided in this guide were designed to achieve a minimum weekly delivered Kt/V of 1.7 and to minimize patient burden. The sample prescriptions must not be considered medical advice and are not a substitute for clinical judgement.11

Ultrafiltration: ≥ 1.0 L/day. Adjustment of dialysis solutions including dextrose and icodextrin to meet the patient’s UF requirement is necessary. UF plays an important role in obtaining clearance. Increasing or decreasing UF also impacts clearance11

Residual Kidney Function: For patients with ≥ 2 mL/min of RKF, prescriptions are based on kidney urea clearance11

A glucose-sparing strategy, using 1.5% and 2.5% dextrose solutions, was applied in modeling. Under these modeling assumptions, use of 4.25% was therefore precluded. However, 4.25% dextrose solutions can be used in situations of fluid overload11

Extraneal (icodextrin) PD solution contraindications. Extraneal (icodextrin) is contraindicated in patients with a known allergy to cornstartch or icodextrin, in patients with maltose or isomaltose intolerance, in patients with glycogen storage disease, and in patients with pre-existing severe lactic acidosis.

Click here for Extraneal PD solution indications and important risk information, including a boxed warning for a dangerous drug-device interaction with non-specific blood glucose monitors and test strips.